11.30.22 -- Biology Meets Computer Science For Next-Gen Biologics Drug Discovery

Learn how an on-line cell counting platform can improve process and product understanding through real-time attribute monitoring, plus more.

Although many quality processes may seem one-size-fits-all, nuances surrounding how a CDMO onboards and operates will affect the speed, efficiency, and outcome of your projects.

Cost efficiencies and expertise again go hand in hand, with companies often outsourcing or partnering primarily to gain access to manufacturing know-how.

A CDMO’s ability to scale seamlessly between bioreactor sizes is critical when adopting a client’s manufacturing process.

To prevent costly changes to a manufacturing process, it is important to assess each operation unit for efficiency of adventitious agent removal or inactivation during downstream process development.

While identification and quantification of HCPs by mass spectrometry is a powerful complementary method to ELISA, HCPs are often masked by drug substances. 

Explore ways to tackle the process step of freezing and thawing when it comes to manufacturing quality biopharmaceutical products, such as ADCs, at scale.

Learn from an industry expert how important it is for companies to be compliant with data integrity and to ensure the trustworthiness and reliability of electronic records.

Due to its modularity, the SMARTag conjugation platform can be broadly applied to various disease contexts. It leverages ease of analytics and a critical combination of efficacy and tolerability.

In a recent episode of Business of Biotech, Philogen CEO Dr. Dario Neri sat down to explore his journey from academia to startups, as well as Philogen's own trajectory.

This webinar describes the advantages of single use and how these technologies overcome the challenges presented by conventional approaches to manufacturing.

Specializing in oncology, anti-infective, and complex formulations, the facility provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

Explore the power of electron activated dissociation (EAD) for confident identification and unambiguous localization of O-linked glycosylation in etanercept.

Streamline the downstream process using variable pathlength technology to determine the DBC of affinity chromatography resins to produce reliable data more effectively and efficiently.